177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression

Journal of Nuclear Medicine

Volumn 50, Issue 12, 2009, Pages 2017-2024

  Maddalena, Mary Ellen ^a   Fox, Jaclyn ^a   Chen, Jianqing ^a   Feng, Weiwei ^a   Cagnolini, Aldo ^a   Linder, Karen E ^a   Tweedle, Michael F ^a   Nunn, Adrian D ^a   Lantry, Laura E ^a  

^a Bracco Research USA   (United States)

Author keywords

177Lu; Gastrin releasing peptide; Imaging; Prostate cancer; Radiotherapeutics

Indexed keywords

AMBA LU 177; ANDROGEN; ANTINEOPLASTIC AGENT; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; BOMBESIN RECEPTOR; DIAGNOSTIC AGENT; DO3A CH2CO G 4 AMINOBENZOYL Q W A V G H L M NH2; DO3A-CH2CO-G-4-AMINOBENZOYL-Q-W-A-V-G-H-L-M-NH2; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL HETEROGENEITY; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RECEPTOR BINDING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; METASTASIS; MICROVASCULATURE; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR BLOOD FLOW; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROSTATE TUMOR; RADIOMETRY; SCINTISCANNING; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; AUTORADIOGRAPHY; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; NEOPLASM METASTASIS; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RADIOMETRY; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION;

EID: 73349138610     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.064444     Document Type: Article

References (29)

1. American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society; 2008.
2. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64:9209-9216.
3. Ohki-Hamazaki H, Iwabuchi M, Maekawa F. Development and function of bombesin-like peptides and their receptors. Int J Dev Biol. 2005;49:293-300.
4. Woodruff GN, Hall MD, Reynolds T, Pinnock RD. Bombesin receptors in the brain. Ann N Y Acad Sci. 1996;780:223-243.
5. Sunday ME. Tissue-specific expression of the mammalian bombesin gene. Ann N Y Acad Sci. 1988;547:95-113.
6. Nagy A, Schally AV. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr Pharm Des. 2005;11:1167-1180.
7. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
8. 99mTc- Leu13-BN1). Cancer Biother Radiopharm. 2004;19:245-252.
9. 4] bombesin by tumor cells. Prostate. 1994;25:29-38.
10. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate; relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
11. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med. 2006;47:1144-1152.
12. Panigone S, Nunn AD. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy. Q J Nucl Med Mol Imaging. 2006;50:310-321.
13. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev. 1998-1999;17: 361-371.
14. 177Lu-labeled radiotherapeutic compound, and NMR structural elucidation of the ligand and its Lu and Hf complexes. Inorg Chem. 2009;48: 3114-3124.
15. Han Z, Slack RS, Wenping L, Papadopoulos V. Expression of peripheral benzodiazepine receptor (PBR) in human tumors: relationship to breast, colorectal, and prostate tumor progression. J Receptor and Sig Trans Res. 2003;23: 225-238.
16. Therasse P, Arbuck S, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
17. 177Lu-AMBA in PC-3 tumor bearing mice [abstract]. J Nucl Med. 2007;48(suppl 2):79P.
18. Baum RP, Prasad V, Mutloka N, et al. Molecular imaging of bombesin receptors in various tumors by Ga-68 AMBA PET/CT: first results [abstract]. J Nucl Med. 2007;48(suppl 2):79P.
19. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685-693.
20. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 2002;62:5381-5385.
21. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem. 2007;101:937-949.
22. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005;15:102-111.
23. 177Lu-AMBA. Eur J Nucl Med Mol Imaging. 2007;34:95-100.
24. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Met Rev. 1990;9:267-282.
25. Hashizume H, Baluk P, Shunichi M. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol. 2000;156:1363-1380.
26. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155-1159.
27. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64: 3731-3736.
28. Wildiers H, Guetens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer. 2003;88:1979-1986.
29. Cardile V, Bellia M, Lombardo L, et al. Distinct response to ionizing radiation of human prostate cell lines. Oncol Rep. 2005;14:981-985.